A recent prospective trial, the proPSMA study, showed superior specificity and sensitivity of Positron emission tomography (PET) ‐ Prostate‐specific membrane antigen (PSMA) imaging compared standard Computerized tomography (CT) and bone scan for staging of recently diagnosed high‐risk local prostate carcinoma for curative intent treatment. The gene discussed is FOLH1; the disease is prostate carcinoma.